{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:48:27Z","timestamp":1776988107454,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T00:00:00Z","timestamp":1370908800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1245\/s10434-013-3025-3","type":"journal-article","created":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T15:37:30Z","timestamp":1370878650000},"page":"2822-2827","source":"Crossref","is-referenced-by-count":6,"title":["Prognosis in Women with Breast Cancer and Private Extra Insurance Coverage"],"prefix":"10.1245","volume":"20","author":[{"given":"Juan J.","family":"Grau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Zanon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Caso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araceli","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Biete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,11]]},"reference":[{"key":"3025_CR1","unstructured":"EUROCARE 4. Survival of cancer patients in Europe, 1995\u20132002: the EUROCARE 4 study. Edited by Riccardo Capocaccia et al. Eur J Cancer. 2009;45:901\u20131094."},{"key":"3025_CR2","unstructured":"National Comprehensive Cancer Network (NCCN). Practice guidelines in oncology, 2002. http:\/\/www.nccn.org . Accessed 1 Mar 2002."},{"issue":"Suppl 2","key":"3025_CR3","doi-asserted-by":"crossref","first-page":"ii7","DOI":"10.1093\/annonc\/mdn071","volume":"19","author":"B Pestalozzi","year":"2008","unstructured":"Pestalozzi B, Castiglione M. Primary breast cancer: ESMO clinical recommentations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):ii7\u20139.","journal-title":"Ann Oncol"},{"key":"3025_CR4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0009-739X(07)71689-5","volume":"82","author":"A Pi\u00f1ero","year":"2007","unstructured":"Pi\u00f1ero A, Gim\u00e9nez J, Merck B, et al. Consensus meeting on sentinel lymph node biopsy in breast cancer. Spanish society of mastology and breast disease. Cir Esp. 2007;82:146\u20139.","journal-title":"Cir Esp"},{"key":"3025_CR5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/annonc\/mdg260","volume":"14","author":"M Martin","year":"2003","unstructured":"Martin M, Villar A, Sole-Calvo A, et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol. 2003;14:833\u201342.","journal-title":"Ann Oncol"},{"key":"3025_CR6","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687\u2013717.","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"3025_CR7","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2004.08.125","volume":"22","author":"E Alba","year":"2004","unstructured":"Alba E, Mart\u00edn M, Ramos M, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol. 2004;22:2587\u201393.","journal-title":"J Clin Oncol"},{"key":"3025_CR8","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302\u201313.","journal-title":"N Engl J Med"},{"key":"3025_CR9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"2","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;2:1431\u20139.","journal-title":"J Clin Oncol"},{"issue":"9169","key":"3025_CR10","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","volume":"353","author":"B Fisher","year":"1999","unstructured":"Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993\u20132000.","journal-title":"Lancet"},{"key":"3025_CR11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081\u201392.","journal-title":"N Engl J Med"},{"key":"3025_CR12","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss PE, Ingle JN, Silvana Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793\u2013802.","journal-title":"N Engl J Med"},{"key":"3025_CR13","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673\u201384.","journal-title":"N Engl J Med"},{"key":"3025_CR14","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ijc.11226","volume":"106","author":"M Sant","year":"2003","unstructured":"Sant M, Allemani C, Capocaccia R, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer. 2003;106:416\u201322.","journal-title":"Int J Cancer"},{"key":"3025_CR15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3747\/co.v17i2.467","volume":"17","author":"DH Cowan","year":"2010","unstructured":"Cowan DH. Vera Peters and the conservative management of early-stage breast cancer. Curr Oncol. 2010;17:50\u20134.","journal-title":"Curr Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-013-3025-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-013-3025-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-013-3025-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T17:07:39Z","timestamp":1551200859000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-013-3025-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,11]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["3025"],"URL":"https:\/\/doi.org\/10.1245\/s10434-013-3025-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,11]]}}}